Hit to lead optimization of isopentenyl chalcones as novel MTHFD2 inhibitors for cancer treatment: design, synthesis, in-vitro, in-vivo and in-silico studies
- 3 May 2025
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 292, 117703
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82173857, 82373913, 82373739)
- Shanghai Municipal Education Commission
- National Key Research and Development Program of China (2023YFA1802000)
This publication has 34 references indexed in Scilit:
- Total synthesis/semi-synthesis of natural isopentenyl flavonoids with inhibitory activity on NLRP3 inflammasomeBioorganic & Medicinal Chemistry Letters, 2024
- Reactive oxygen species (ROS) in cancer pathogenesis and therapy: An update on the role of ROS in anticancer action of benzophenanthridine alkaloidsBiomedicine & Pharmacotherapy, 2021
- Oxidative stress and dietary phytochemicals: Role in cancer chemoprevention and treatmentCancer Letters, 2018
- Reactive oxygen species (ROS) are a key determinant of cancer's metabolic phenotypeInternational Journal of Cancer, 2017
- Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticalsCancer Letters, 2017
- Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate PathwayCell Metabolism, 2016
- Increased MTHFD2 expression is associated with poor prognosis in breast cancerTumor Biology, 2014
- NMR spectral assignments of isoprenylated flavanones from Sophora tonkinensisMagnetic Resonance in Chemistry, 2008
- Antiulcer and gastroprotective effects of solon, a synthetic flavonoid derivative of sophoradin. Role of endogenous prostaglandinsEuropean Journal of Pharmacology, 1986
- A general method applicable to the search for similarities in the amino acid sequence of two proteinsJournal of Molecular Biology, 1970